Table 3. WMD or OR (95%CI) of seven treatment modalities of four endpoints.
| WMD/OR(95%CI) | ||||||
|---|---|---|---|---|---|---|
| Efficacy | ||||||
| PFS (months) | ||||||
| A | 1.60 (0.30, 2.96) | 1.91 (0.09, 3.82) | 1.22 (−0.13, 2.61) | 1.45 (−0.49, 3.26) | ||
| −1.60 (−2.96, −0.30) | B | 0.32 (−1.93, 2.62) | −0.38 (−2.27, 1.50) | −0.16 (−2.49, 2.12) | ||
| −1.91 (−3.82, −0.09) | −0.32 (−2.62, 1.93) | C | −0.71 (−3.00, 1.59) | −0.48 (−3.17, 2.13) | ||
| −1.22 (−2.61, 0.13) | 0.38 (−1.50, 2.27) | 0.71 (−1.59, 3.00) | E | 0.23 (−2.12, 2.50) | ||
| −1.45 (−3.26, 0.49) | 0.16 (−2.12, 2.49) | 0.48 (−2.13, 3.17) | −0.23 (−2.50, 2.12) | G | ||
| OS (months) | ||||||
| A | 1.30 (0.35, 2.32) | 0.54 (−0.67, 1.78) | 0.39 (−1.42, 2.24) | |||
| −1.30 (−2.32, −0.35) | B | −0.76 (−2.36, 0.79) | −0.91 (−2.98, 1.14) | |||
| −0.54 (−1.78, 0.67) | 0.76 (−0.79, 2.36) | E | −0.14 (−2.29, 2.05) | |||
| −0.39 (−2.24, 1.42) | 0.91 (−1.14, 2.98) | 0.14 (−2.05, 2.29) | G | |||
| ORR | ||||||
| A | 1.64 (0.47, 5.64) | 0.60 (0.13, 2.36) | 1.61 (0.57, 4.75) | 0.26 (0.03, 1.76) | 0.70 (0.15, 3.61) | 2.18 (0.58, 8.46) |
| 0.61 (0.18, 2.11) | B | 0.37 (0.05, 2.26) | 0.99 (0.19, 5.29) | 0.16 (0.01, 1.59) | 0.43 (0.06, 3.24) | 1.35 (0.23, 7.85) |
| 1.66 (0.42, 7.92) | 2.73 (0.44, 19.02) | C | 2.74 (0.47, 16.71) | 0.45 (0.03, 4.81) | 1.19 (0.15, 10.31) | 3.77 (0.56, 27.36) |
| 0.62 (0.21, 1.76) | 1.01 (0.19, 5.32) | 0.36 (0.06, 2.11) | E | 0.16 (0.01, 1.44) | 0.43 (0.07, 3.00) | 1.34 (0.25, 7.31) |
| 3.85 (0.57, 36.17) | 6.36 (0.63, 83.38) | 2.22 (0.21, 31.35) | 6.24 (0.70, 76.33) | F | 2.78 (0.24, 42.89) | 8.38 (0.84, 113.02) |
| 1.43 (0.28, 6.61) | 2.31 (0.31, 16.33) | 0.84 (0.10, 6.62) | 2.31 (0.33, 14.25) | 0.36 (0.02, 4.20) | G | 3.15 (0.39, 22.39) |
| 0.46 (0.12, 1.72) | 0.74 (0.13, 4.42) | 0.27 (0.04, 1.78) | 0.74 (0.14, 4.01) | 0.12 (0.01, 1.19) | 0.32 (0.04, 2.55) | H |
| DCR | ||||||
| A | 1.79 (0.79, 4.10) | 1.31 (0.45, 3.94) | 1.41 (0.61, 3.29) | 1.94 (0.71, 5.30) | 1.62 (0.67, 3.80) | |
| 0.56 (0.24, 1.27) | B | 0.73 (0.19, 2.93) | 0.79 (0.24, 2.56) | 1.09 (0.29, 3.85) | 0.90 (0.27, 2.91) | |
| 0.76 (0.25, 2.24) | 1.38 (0.34, 5.25) | C | 1.09 (0.28, 4.08) | 1.48 (0.33, 6.59) | 1.23 (0.29, 4.74) | |
| 0.71 (0.30, 1.64) | 1.27 (0.39, 4.19) | 0.92 (0.24, 3.60) | E | 1.38 (0.37, 4.94) | 1.15 (0.33, 3.71) | |
| 0.52 (0.19, 1.41) | 0.92 (0.26, 3.41) | 0.67 (0.15, 3.00) | 0.73 (0.20, 2.70) | G | 0.83 (0.22, 3.15) | |
| 0.62 (0.26, 1.48) | 1.12 (0.34, 3.75) | 0.81 (0.21, 3.41) | 0.87 (0.27, 3.03) | 1.20 (0.32, 4.64) | H | |
Notes: WMD = Weighted mean difference; OR = Odds ratio; 95% CI = 95% confidence interval, Weighted mean difference or odds ratio (95% CI) below the treatments should be read from row to column while above the treatments should be read from column to row. PFS and OS are stated as WMD (95% CI), while ORR and DCR are presented as OR (95% CI). PFS = Progression-free survival; OS = overall survival; ORR = overall response rate; DCR = Disease control rate; A = Erlotinib + Placebo; B = Erlotinib + Tivantinib; C = Erlotinib + Celecoxib; E = Erlotinib + Sunitinib; F = Erlotinib + Entinostat; G = Erlotinib + Sorafenib; H = Erlotinib + Bevacizumab.